^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
Breyanzi (lisocabtagene maraleucel)
i
Other names: JCAR017, anti-CD19-EGFRt-4-1BB-zeta modified CAR CD8+ and CD4+ T lymphocyte therapy, CD19-CAR T cell immunotherapy, CD19 specific CAR T cells also expressing an EGFRt, anti-CD19/EGFRt/4-1BB/zeta modified CAR CD8+ and CD4+ T lymphocyte therapy, JCAR 017, liso-cel, JCAR-017
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
BMS
Drug class:
CD19-targeted CAR-T immunotherapy
Related drugs:
